Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Utah Medical Products (UTMD) EBITDA Margin (2016 - 2025)

Utah Medical Products has reported EBITDA Margin over the past 16 years, most recently at 31.93% for Q4 2025.

  • Quarterly results put EBITDA Margin at 31.93% for Q4 2025, up 2228.0% from a year ago — trailing twelve months through Dec 2025 was 35.77% (up 491.0% YoY), and the annual figure for FY2025 was 35.77%, up 490.0%.
  • EBITDA Margin for Q4 2025 was 31.93% at Utah Medical Products, up from 22.98% in the prior quarter.
  • Over the last five years, EBITDA Margin for UTMD hit a ceiling of 51.17% in Q4 2022 and a floor of 9.65% in Q4 2024.
  • Median EBITDA Margin over the past 5 years was 30.63% (2024), compared with a mean of 31.22%.
  • Peak annual rise in EBITDA Margin hit 2655bps in 2024, while the deepest fall reached -3596bps in 2024.
  • Utah Medical Products' EBITDA Margin stood at 32.1% in 2021, then soared by 59bps to 51.17% in 2022, then decreased by -11bps to 45.62% in 2023, then crashed by -79bps to 9.65% in 2024, then soared by 231bps to 31.93% in 2025.
  • The last three reported values for EBITDA Margin were 31.93% (Q4 2025), 22.98% (Q3 2025), and 48.99% (Q2 2025) per Business Quant data.